Wells Fargo Maintains Equal-Weight on C4 Therapeutics, Raises Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila has maintained an Equal-Weight rating on C4 Therapeutics (NASDAQ:CCCC) and increased the price target from $7 to $8.
May 09, 2024 | 3:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo maintains an Equal-Weight rating on C4 Therapeutics and raises the price target from $7 to $8.
The increase in price target by a reputable analyst like Derek Archila suggests a positive outlook on the stock, potentially leading to increased investor confidence and a short-term price increase.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100